CN115515956A - 一种苯并咪唑类衍生物及其制备方法和医药用途 - Google Patents

一种苯并咪唑类衍生物及其制备方法和医药用途 Download PDF

Info

Publication number
CN115515956A
CN115515956A CN202180030750.1A CN202180030750A CN115515956A CN 115515956 A CN115515956 A CN 115515956A CN 202180030750 A CN202180030750 A CN 202180030750A CN 115515956 A CN115515956 A CN 115515956A
Authority
CN
China
Prior art keywords
methyl
group
mmol
oxetan
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180030750.1A
Other languages
English (en)
Other versions
CN115515956B (zh
Inventor
吴俊军
陆银锁
肖瑛
周鹏
滕耀辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Salubris Pharmaceuticals Co Ltd
Original Assignee
Shenzhen Salubris Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharmaceuticals Co Ltd filed Critical Shenzhen Salubris Pharmaceuticals Co Ltd
Publication of CN115515956A publication Critical patent/CN115515956A/zh
Application granted granted Critical
Publication of CN115515956B publication Critical patent/CN115515956B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

一种涉及式(I)的化合物、其制备方法及其在医药上的应用。具体而言，一种涉及式(I)的化合物或其立体异构体、互变异构体、药学上可接受的盐。这些化合物是胰高血糖样肽‑1受体(GLP‑1R)的激动剂，还涉及包含这些化合物的药物组合物以及使用该化合物治疗糖尿病等疾病的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN202180030750.1A 2020-09-29 2021-09-27 一种苯并咪唑类衍生物及其制备方法和医药用途 Active CN115515956B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN2020110509441 2020-09-29
CN202011050944 2020-09-29
CN202011311263 2020-11-20
CN2020113112636 2020-11-20
CN202011491886 2020-12-17
CN2020114918866 2020-12-17
CN202110634855 2021-06-08
CN202110634855X 2021-06-08
PCT/CN2021/120978 WO2022068772A1 (zh) 2020-09-29 2021-09-27 一种苯并咪唑类衍生物及其制备方法和医药用途

Publications (2)

Publication Number Publication Date
CN115515956A true CN115515956A (zh) 2022-12-23
CN115515956B CN115515956B (zh) 2024-06-25

Family

ID=80949690

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180030750.1A Active CN115515956B (zh) 2020-09-29 2021-09-27 一种苯并咪唑类衍生物及其制备方法和医药用途

Country Status (2)

Country Link
CN (1) CN115515956B (zh)
WO (1) WO2022068772A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115461334A (zh) * 2020-11-27 2022-12-09 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022552735A (ja) 2019-10-25 2022-12-19 ギリアード サイエンシーズ， インコーポレイテッド Ｇｌｐ－１ｒ調節化合物
WO2022028572A1 (en) 2020-08-06 2022-02-10 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4204415A1 (en) 2020-08-28 2023-07-05 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2022109182A1 (en) 2020-11-20 2022-05-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
EP4304711A1 (en) * 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
US20220306614A1 (en) * 2021-03-11 2022-09-29 Gilead Sciences, Inc. Glp-1r modulating compounds
MX2023012418A (es) 2021-04-21 2023-10-31 Gilead Sciences Inc Compuestos de modulacion de glp-1r de carboxi-bencimidazol.
TWI843104B (zh) 2021-05-20 2024-05-21 美商美國禮來大藥廠 類升糖素肽1受體促效劑
MX2024004131A (es) 2021-10-05 2024-04-22 Astrazeneca Ab Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1.
WO2023057414A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
WO2023090859A1 (ko) * 2021-11-17 2023-05-25 일동제약(주) 아이속사졸 유도체의 제조 방법 및 그의 신규한 중간체
WO2023111144A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023111145A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
WO2024107781A1 (en) 2022-11-16 2024-05-23 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110325530A (zh) * 2016-12-16 2019-10-11 辉瑞大药厂 Glp-1受体激动剂及其用途
WO2019239371A1 (en) * 2018-06-15 2019-12-19 Pfizer Inc. Glp-1 receptor agonists and uses thereof
WO2019239319A1 (en) * 2018-06-13 2019-12-19 Pfizer Inc. Glp-1 receptor agonists and uses thereof
WO2020103815A1 (en) * 2018-11-22 2020-05-28 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof
WO2020207474A1 (en) * 2019-04-12 2020-10-15 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113480534B (zh) * 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110325530A (zh) * 2016-12-16 2019-10-11 辉瑞大药厂 Glp-1受体激动剂及其用途
WO2019239319A1 (en) * 2018-06-13 2019-12-19 Pfizer Inc. Glp-1 receptor agonists and uses thereof
WO2019239371A1 (en) * 2018-06-15 2019-12-19 Pfizer Inc. Glp-1 receptor agonists and uses thereof
WO2020103815A1 (en) * 2018-11-22 2020-05-28 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof
WO2020207474A1 (en) * 2019-04-12 2020-10-15 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115461334A (zh) * 2020-11-27 2022-12-09 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
CN115461334B (zh) * 2020-11-27 2024-06-21 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途

Also Published As

Publication number Publication date
WO2022068772A1 (zh) 2022-04-07
CN115515956B (zh) 2024-06-25

Similar Documents

Publication Publication Date Title
CN115515956A (zh) 一种苯并咪唑类衍生物及其制备方法和医药用途
WO2022111624A1 (zh) 一种苯并咪唑类衍生物及其制备方法和医药用途
US11242334B2 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
US10030016B2 (en) Heterocyclic compounds useful as PDK1 inhibitors
US10023557B2 (en) Therapeutic inhibitory compounds
EP2820017B1 (en) Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives
EP3724191B1 (en) 5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
US20210188868A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
CN113631535B (zh) 治疗铁死亡相关紊乱的杂芳基和双杂环芳基衍生物
US20170216262A1 (en) Amido spirocyclic amide and sulfonamide derivatives
US9181272B2 (en) Aldosterone synthase inhibitors
KR20160122736A (ko) 헤테로아릴 및 이의 용도
US11667624B2 (en) Indole compounds as androgen receptor modulators
CN115594669A (zh) 一种并环类衍生物及其制备方法和医药用途
WO2023016535A1 (zh) 一种三联吡啶二酮化合物或其盐及其制备方法与应用
WO2012167606A1 (zh) 吡啶并萘啶类PI3K和mTOR双重抑制剂及其制备与应用
KR20180038047A (ko) 인간 면역결핍 바이러스 복제의 억제제로서 피리딘-3-일 아세트산 유도체
CN115703792A (zh) 一种并三环类衍生物及其制备方法和医药用途
CN108948019A (zh) 黏着斑激酶抑制剂及其用途
WO2024022481A1 (zh) 苯基取代的二氢萘啶类化合物及其制备与用途
US20230348439A1 (en) Indole compounds as androgen receptor modulators
EP4330233A1 (en) Phenyl -o-quinoline, quinazoline, thienopyridine, thienopyrimidine, pyrrolopyridine, pyrrolopyrimidine compounds having anticancer activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant